Articles tagged with: Doxorubicin
Press Releases»
Silver Spring, MD (Official Notice) - FDA is providing information on the availability of doxorubicin hydrochloride liposome injection to supply the U.S. market.
Doxil® (doxorubicin hydrochloride liposome injection) is distributed by Janssen Products, LP and has been manufactured under contract by Ben Venue Laboratories, Inc. On September 25, 2013, Janssen notified healthcare professionals of an interruption of supply of Doxil resulting from manufacturing issues at Ben Venue Laboratories. On October 3, 2013, Ben Venue Laboratories announced their plans to cease all manufacturing by the end of 2013.
Sun Pharma Global has confirmed …
News»
Results from a small Phase 2 study conducted throughout Japan suggest that a combination of Velcade, doxorubicin, and intermediate-dose dexamethasone is effective in patients with relapsed or refractory multiple myeloma.
Most patients (89 percent) responded to treatment, with a third of them achieving a complete or near complete response. In addition, the median progression-free survival was 12.1 months.
According to the Japanese researchers, the findings from this study are comparable to those from previous studies that examined the effectiveness of the Velcade (bortezomib), doxorubicin (Adriamycin), and
NewsFlash »
Biotest AG Starts Clinical Trial Of BT-062 Combination Therapy – The German pharmaceutical company Biotest AG has begun a Phase 1/2 clinical trial of BT-062 in combination with Revlimid (lenalidomide) and dexamethasone (Decadron) in patients with relapsed and/or refractory multiple myeloma. BT-062 consists of a chemotherapeutic drug combined with an antibody that helps deliver the drug to myeloma and other cancer cells. BT-062 alone has demonstrated anti-myeloma activity and good tolerability in relapsed and refractory myeloma patients. Furthermore, preclinical studies have shown BT-062 to be more effective when combined with Revlimid. For more information, please see the Biotest AG press release and the clinical trial description.
Kyprolis And Oprozomib May Decrease Bone Damage In Multiple Myeloma – The results of a preclinical study suggest that Kyprolis (carfilzomib) and oprozomib may prevent bone loss in multiple myeloma. Kyprolis and oprozomib are both being developed by Onyx Pharmaceuticals, and both belong to the same class of drugs as Velcade (bortezomib), known as proteasome inhibitors. Kyprolis was approved last week by the U.S. Food and Drug Administration for the treatment of people with multiple myeloma who have received at least two prior therapies (see related Beacon news). Oprozomib, which will be administered orally, is still in the early clinical development phase. In this study, researchers found that carfilzomib and oprozomib enhanced bone formation and decreased bone destruction in healthy mice. Additionally, in mice with multiple myeloma, treatment with carfilzomib or oprozomib resulted in a smaller tumor burden and prevented bone destruction. For more information, please see the study in Leukemia (abstract).
NDC May Overcome Multidrug Resistance And Prevent Doxorubicin-Induced Heart Disease In Myeloma Patients – The results of a recent preclinical study show that a doxorubicin-curcumin compound called NanoDoxCurc (NDC) may overcome resistance to doxorubicin (Adriamycin) while preventing treatment-related heart disease. Doxorubicin is a common anticancer agent that becomes less effective in cancer cells demonstrating multidrug resistance. In higher doses, doxorubicin can overcome multidrug resistance, but is also associated with heart disease. In this study, NDC-treated mice with multiple myeloma demonstrated lower tumor burdens than mice treated with doxorubicin alone. Furthermore, mice treated with NDC did not experience heart complications. The study investigators believe these findings indicate that NDC may be a safe and long-lasting cancer therapy. For more information, please see the study in Oncotarget.
BCMA Levels May Be A Disease Marker In Multiple Myeloma – In a recent study, researchers found that B-cell maturation antigen (BCMA) levels in the blood are elevated in multiple myeloma patients and are associated with disease status and overall survival. BCMAs can be found on the surface of both normal and cancerous B-cells, a type of white blood cell. In the current study, BCMA levels in the blood were higher in multiple myeloma patients compared to those in healthy adults. Furthermore, patients with progressive disease demonstrated higher BCMA levels than those who were responsive to treatment. After a median follow-up time of 11 months, patients with BCMA levels above the median had shorter overall survival times than patients below the median. For more information, please see the study in the British Journal of Haematology (abstract).
NewsFlash »
INNO-206 Shows Activity Against Myeloma - Results of a preclinical study show that the investigational drug INNO-206 inhibits blood vessel formation and reduces cell growth in myeloma cell lines. The drug showed these effects when tested alone; additionally it enhanced the efficacy of Velcade (bortezomib) when tested in combination. INNO-206 is a derivative of the chemotherapy agent doxorubicin (Adriamycin). This study also showed that INNO-206 was safer in mice than doxorubicin and therefore could be administered at higher doses. For information, please see the study in Clinical Cancer Research (abstract).
TRAIL-Doxorubicin Combination May Eradicate Myeloma Cells – Results of a preclinical study show that a combination of doxorubicin and TRAIL, a protein that induces cell death, was able to eradicate myeloma cell lines. In particular, the TRAIL-doxorubicin combination successfully eliminated cells that are implicated in tumor initiation as well as tumor growth. According to the study investigators, these findings offer a promising new approach to finding a cure for multiple myeloma. For more information, please see the study in PloS One.
Relatives Of Multiple Myeloma Patients Have Increased Risk Of MGUS – Results of a study conducted at the Mayo Clinic indicate that first-degree relatives of multiple myeloma patients are 3.4 times as likely to develop light-chain monoclonal gammopathy of undetermined significance (MGUS) compared to the general population. A previous study also showed that these relatives are at an increased risk of developing heavy-chain MGUS. For more information, please see the study in the British Journal of Hematology (abstract).
IMF Myeloma Workshop For Patients And Families – The International Myeloma Foundation (IMF) will be hosting a workshop for multiple myeloma patients and their families on June 23 in Milwaukee, WI. Dr. Ayman Saad from the Medical College of Wisconsin, Dr. Natalie Callander from the University of Wisconsin School of Medicine, and nurse Tiffany Richards from the MD Anderson Cancer Center in Houston will speak about topics including treatment options, managing side effects, and local clinical trials. For more information or to register, please visit the IMF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
Myeloma specialists from the Czech Republic have published clinical trial results that shed further light on chromosomal abnormalities and their impact on survival in newly diagnosed multiple myeloma patients.
Specifically, the researchers found that patients with three or more chromosomal abnormalities, a gain in the 1q21 region, or the translocation t(4;14) have reduced survival compared to patients without such abnormalities.
According to the researchers, their findings highlight the importance of chromosomal abnormalities when considering treatment options for myeloma patients.
They note, however, that their findings need to be confirmed in a prospective, …
News»
The results of a recent Japanese study suggest that a vincristine-doxorubicin-dexamethasone regimen without intermittent high-dose dexamethasone reduces the risk of bacterial infection in multiple myeloma patients without affecting the treatment’s efficacy.
Based on these findings, the study authors recommended avoiding the administration of intermittent high-dose dexamethasone with the vincristine-doxorubicin-dexamethasone regimen in myeloma patients at high risk for infection.
The combination treatment of vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (Decadron) plus high-dose pulses of dexamethasone (referred to as VAD-HD) was first approved as a treatment for advanced multiple myeloma.
It …
News»
The results of a number of clinical trials for the treatment of multiple myeloma with Zolinza were presented at the American Society of Hematology (ASH) 2010 annual meeting. The trials, ranging from Phase 1 to Phase 3, studied Zolinza in combination with a variety of approved myeloma drugs for the treatment of both early and advanced stages of the disease.
Zolinza (vorinostat) is manufactured by Merck Pharmaceuticals. It is currently approved for a certain type of lymphoma and is being investigated as a treatment for multiple myeloma (see related Beacon …